
|Articles|December 1, 2006
Case report highlights rationale for neovascular glaucoma treatment
Denver-Intravitreal bevacizumab (Avastin, Genentech) proved to be a successful treatment in a patient with neovascular glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
2
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
3
Glaucoma innovation: Eight themes to watch in 2026
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































